EASD 2026: TRIUMPH-2 data puts retatrutide above the incretin ceiling in T2D

Phase 3positiveretatrutidePositive

AI Analysis

Summary

TRIUMPH-2 Phase III trial results for retatrutide were presented at EASD 2026, demonstrating efficacy above the incretin ceiling in overweight patients with type 2 diabetes. The positive data supports the drug's competitive positioning in the T2D market.

Clinical Trial Data

Phase

Phase III

Primary Endpoint

Met

NCT ID

NCT05929079

Outcome Details

TRIUMPH-2 Phase III trial data presented at EASD 2026 showing retatrutide performance above the incretin ceiling in overweight patients with T2D

Importance:7/10

Sentiment:

0.70

Phase IIITRIUMPH-2Type 2 DiabetesEASD 2026RetatrutideObesity

Related Companies

$LLY

Read the original article

Published by Clinical Trials Arena on October 2, 2026 12:24 PM

Read Original